Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics Corporation (NYSE: HAE) announced the sale of its subsidiary Inlog Holdings France SAS to Abénex, a private equity firm, to enhance its focus on growth segments. This divestment includes software solutions like EdgeSuite™ and SapaNet™, which optimize operations in blood banks and hospital labs. The transaction is expected to close in Q3 2020, pending customary conditions. CEO Chris Simon emphasized this strategic move aligns with their Innovation Agenda, aiming to improve patient outcomes and maintain leadership in the hematology sector.
Haemonetics Corporation (NYSE: HAE) has announced that its 2020 Annual Meeting of Shareholders will be held virtually on July 21, 2020, at 8 a.m. Eastern Time. This decision is in response to the COVID-19 pandemic to ensure the health of participants. Only shareholders of record as of May 22, 2020 can attend the meeting by using a control number provided in their proxy materials. They are encouraged to vote prior to the meeting. Additional proxy materials have been filed with the SEC regarding voting and participation details.